Related Experiment Video
Updated: May 7, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Apoptotic markers in a prostate cancer cell line: effect of ellagic acid
Luca Vanella1, Claudia Di Giacomo, Rosaria Acquaviva
1Department of Drug Science, Section of Biochemistry, University of Catania, I-95125 Catania, Italy.
Abstract:
Ellagic acid (EA) inhibits cell growth and induces apoptosis in cultured cells; however, the precise molecular mechanism involved in EA-induced apoptosis in prostate cancer cells is unknown. The aim of the present study was to delineate possible apoptotic pathway(s) involved in the EA-mediated chemotherapeutic effects in the LNCaP human prostatic cancer cell line. EA produced anti-proliferative effects through inhibition of rapamycin (mTOR) activation and a reduction in intracellular levels of β-catenin. Moreover, we demonstrated that EA induced apoptosis via downregulation of the anti-apoptotic proteins, silent information regulator 1 (SIRT1), human antigen R (HuR) and heme oxygenase-1 (HO-1). EA modulated the expression of apoptosis-inducing factor (AIF) resulting in a significant increase in reactive oxygen species (ROS) levels and the activation of caspase-3. Finally, we demonstrated that EA reduced both transforming growth factor-β (TGF-β) and interleukin-6 (IL-6) levels. EA treatment resulted in the increased expression of the tumor suppressor protein p21 and increased the percentage of apoptotic cells. In conclusion, the results suggest that EA treatment represents a new and highly effective strategy in reducing prostate cancer carcinogenesis.
Insights
Ellagic acid (EA) inhibits prostate cancer cell growth by inducing apoptosis through multiple molecular pathways. This natural compound offers a promising strategy for reducing prostate cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Prostate cancer remains a significant health concern with limited effective treatments.
- Ellagic acid (EA) shows anti-cancer properties, but its specific mechanisms in prostate cancer are not fully understood.
Purpose of the Study:
- To investigate the molecular mechanisms of EA-induced apoptosis in LNCaP human prostate cancer cells.
- To identify the specific signaling pathways modulated by EA.
Main Methods:
- Cell culture of LNCaP cells treated with EA.
- Analysis of protein expression (mTOR, β-catenin, SIRT1, HuR, HO-1, AIF, p21).
- Measurement of reactive oxygen species (ROS) and caspase-3 activation.
- Quantification of TGF-β and IL-6 levels.
Main Results:
- EA inhibited mTOR activation and reduced β-catenin levels.
- EA downregulated anti-apoptotic proteins (SIRT1, HuR, HO-1) and modulated AIF expression.
- EA increased ROS levels, activated caspase-3, and upregulated p21.
- EA reduced TGF-β and IL-6 levels, leading to increased apoptosis.
Conclusions:
- EA induces apoptosis in prostate cancer cells via multiple pathways, including ROS generation and caspase-3 activation.
- EA's anti-proliferative effects are linked to mTOR and β-catenin inhibition.
- EA represents a potential therapeutic strategy for prostate cancer prevention and treatment.
